• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Covid-19 controversies: the tocilizumab chapter.

作者信息

McCreary Erin K, Meyer Nuala J

机构信息

Department of Medicine, Division of Infectious Diseases, UPMC Health System and the University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA

Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.

出版信息

BMJ. 2021 Jan 27;372:n244. doi: 10.1136/bmj.n244.

DOI:10.1136/bmj.n244
PMID:33504502
Abstract
摘要

相似文献

1
Covid-19 controversies: the tocilizumab chapter.新冠疫情争议：托珠单抗篇章
BMJ. 2021 Jan 27;372:n244. doi: 10.1136/bmj.n244.
2
Promising effects of tocilizumab in COVID-19: A non-controlled, prospective clinical trial.托珠单抗治疗 COVID-19 的疗效：一项非对照、前瞻性临床试验。
Int Immunopharmacol. 2020 Nov;88:106869. doi: 10.1016/j.intimp.2020.106869. Epub 2020 Aug 4.
3
Tocilizumab in Covid-19.托珠单抗治疗新型冠状病毒肺炎
N Engl J Med. 2021 Jan 7;384(1):86-87. doi: 10.1056/NEJMc2032911. Epub 2020 Dec 22.
4
Tocilizumab in Covid-19. Reply.托珠单抗治疗新型冠状病毒肺炎。回复。
N Engl J Med. 2021 Jan 7;384(1):87. doi: 10.1056/NEJMc2032911. Epub 2020 Dec 22.
5
Rationale and evidence on the use of tocilizumab in COVID-19: A systematic review. Authors' reply.托珠单抗用于新型冠状病毒肺炎的理论依据与证据：一项系统评价。作者回复
Pulmonology. 2021 Jan-Feb;27(1):87-88. doi: 10.1016/j.pulmoe.2020.10.003. Epub 2020 Oct 21.
6
Hemophagocytic lymphohistiocytosis in a patient with COVID-19 treated with tocilizumab: a case report.托珠单抗治疗新型冠状病毒肺炎患者并发噬血细胞性淋巴组织细胞增生症：一例报告
J Med Case Rep. 2020 Oct 15;14(1):187. doi: 10.1186/s13256-020-02503-9.
7
Experience with tocilizumab in severe COVID-19 pneumonia after 80 days of follow-up: A retrospective cohort study.托珠单抗治疗 80 天后严重 COVID-19 肺炎的经验：一项回顾性队列研究。
J Autoimmun. 2020 Nov;114:102523. doi: 10.1016/j.jaut.2020.102523. Epub 2020 Jul 16.
8
Tocilizumab for COVID-19: a real 'miracle drug'?托珠单抗治疗新冠肺炎：一种真正的“神药”？
Infect Dis (Lond). 2020 Sep;52(9):681-682. doi: 10.1080/23744235.2020.1780307. Epub 2020 Jun 17.
9
Tocilizumab in COVID-19: Beware the risk of intestinal perforation.托珠单抗治疗新型冠状病毒肺炎：谨防肠穿孔风险。
Int J Antimicrob Agents. 2020 Jul;56(1):106009. doi: 10.1016/j.ijantimicag.2020.106009. Epub 2020 May 7.
10
Use of tocilizumab in multisystem inflammatory syndrome in children associated with severe acute respiratory syndrome coronavirus 2.托珠单抗在与严重急性呼吸综合征冠状病毒2相关的儿童多系统炎症综合征中的应用。
J Pediatr. 2021 Jan;228:315. doi: 10.1016/j.jpeds.2020.09.054. Epub 2020 Oct 26.

引用本文的文献

1
Efficacy and safety of interleukin-6 receptor antagonists in adult patients admitted to intensive care unit with COVID-19: A systematic review and -analysis of randomized controlled trials.白细胞介素-6受体拮抗剂在入住重症监护病房的成年COVID-19患者中的疗效和安全性：一项随机对照试验的系统评价与分析
Prev Med Rep. 2023 Aug;34:102276. doi: 10.1016/j.pmedr.2023.102276. Epub 2023 Jun 7.
2
Public perceptions of the association between drug effectiveness and drug novelty in France during the COVID-19 pandemic.公众对 COVID-19 大流行期间法国药物有效性和新颖性之间关联的看法。
Therapie. 2022 Nov-Dec;77(6):693-701. doi: 10.1016/j.therap.2022.05.001. Epub 2022 May 7.
3
Safety and Efficacy of Tocilizumab 4 or 8 mg/kg in Hospitalized Patients With Moderate to Severe Coronavirus Disease 2019 Pneumonia: A Randomized Clinical Trial.
托珠单抗4或8mg/kg用于中度至重度新型冠状病毒肺炎住院患者的安全性和有效性：一项随机临床试验
Open Forum Infect Dis. 2021 Dec 4;9(1):ofab608. doi: 10.1093/ofid/ofab608. eCollection 2022 Jan.
4
The Drug Repurposing for COVID-19 Clinical Trials Provide Very Effective Therapeutic Combinations: Lessons Learned From Major Clinical Studies.用于COVID-19临床试验的药物重新利用提供了非常有效的治疗组合：从主要临床研究中吸取的经验教训。
Front Pharmacol. 2021 Nov 18;12:704205. doi: 10.3389/fphar.2021.704205. eCollection 2021.
5
Signals were broadly positive for months, but never definitive: the tocilizumab story.数月来，信号广泛向好，但一直无法明确：托珠单抗的故事。
Clin Microbiol Infect. 2022 Mar;28(3):371-374. doi: 10.1016/j.cmi.2021.10.018. Epub 2021 Nov 9.
6
A randomized controlled clinical trial on efficacy and safety of anakinra in patients with severe COVID-19.一项关于阿那白滞素治疗重症 COVID-19 患者的疗效和安全性的随机对照临床试验。
Immun Inflamm Dis. 2022 Feb;10(2):201-208. doi: 10.1002/iid3.563. Epub 2021 Nov 11.
7
Decreased mortality and increased side effects in COVID-19 patients treated with IL-6 receptor antagonists: systematic review and meta-analysis.COVID-19 患者接受白细胞介素 6 受体拮抗剂治疗后死亡率降低且副作用增加：系统评价和荟萃分析。
Sci Rep. 2021 Nov 2;11(1):21522. doi: 10.1038/s41598-021-00726-4.
8
Mapping Pulmonary and Systemic Inflammation in Preschool Aged Children With Cystic Fibrosis.绘制学龄前囊性纤维化儿童的肺部和全身炎症图谱。
Front Immunol. 2021 Oct 15;12:733217. doi: 10.3389/fimmu.2021.733217. eCollection 2021.
9
Real-life use of tocilizumab with or without corticosteroid in hospitalized patients with moderate-to-severe COVID-19 pneumonia: A retrospective cohort study.托珠单抗在住院的中重度 COVID-19 肺炎患者中联合或不联合皮质类固醇的实际应用：一项回顾性队列研究。
PLoS One. 2021 Sep 10;16(9):e0257376. doi: 10.1371/journal.pone.0257376. eCollection 2021.
10
Risk of Reactivation of Hepatitis B Virus (HBV) and Tuberculosis (TB) and Complications of Hepatitis C Virus (HCV) Following Tocilizumab Therapy: A Systematic Review to Inform Risk Assessment in the COVID-19 Era.托珠单抗治疗后乙型肝炎病毒（HBV）再激活、结核病（TB）及丙型肝炎病毒（HCV）并发症的风险：一项为COVID-19时代风险评估提供信息的系统评价
Front Med (Lausanne). 2021 Aug 20;8:706482. doi: 10.3389/fmed.2021.706482. eCollection 2021.